Descriptive account of the first use of the LeVe CPAP System, a new frugal CPAP System, in adult patients with COVID-19 Pneumonitis in Uganda.
Anaesthetics
COVID-19
CPAP
Global Health
LMIC
NIV
Pandemic
Sustainability
Journal
Tropical medicine and health
ISSN: 1348-8945
Titre abrégé: Trop Med Health
Pays: Japan
ID NLM: 101215093
Informations de publication
Date de publication:
07 Aug 2023
07 Aug 2023
Historique:
received:
01
04
2023
accepted:
27
07
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
6
8
2023
Statut:
epublish
Résumé
Continuous positive airway pressure (CPAP) has been a key treatment modality for Coronavirus Disease 2019 (COVID-19) worldwide. Globally, the demand for CPAP outstripped the supply during the pandemic. The LeVe CPAP System was developed to provide respiratory support for treatment of COVID-19 and tailored for use in low- and middle-income country (LMIC) settings. Prior to formal trial approval, received in November 2021, these devices were used in extremis to support critically unwell adult patients requiring non-invasive ventilatory support. This is a retrospective descriptive review of adult patients with COVID-19 pneumonitis, who were treated with advanced respiratory support (CPAP and/or high-flow nasal oxygen, HFNO) at Mengo Hospital, Uganda. Patients were treated with the LeVe CPAP System, Elisa CPAP and/or AIRVO™ HFNO. Treatment was escalated per standard local protocols for respiratory failure, and CPAP was the maximum respiratory support available. Data were collected on patient characteristics, length of time of treatment, clinical outcome, and any adverse events. Overall 333 patients were identified as COVID-19 positive, 44 received CPAP ± HFNO of which 43 were included in the study. The median age was 58 years (range 28-91 years) and 58% were female. The median duration of advanced respiratory support was 7 days (range 1-18 days). Overall (all device) mortality was 49% and this was similar between those started on the LeVe CPAP System and those started non-LeVe CPAP System devices (50% vs 47%). The LeVe CPAP system was the most used CPAP device during the pandemic, bringing the hospital's number of available HFNO/CPAP devices from two to 14. They were a critical resource for providing respiratory support to the sickest group of patients when no alternative devices were available. The devices appear to be safe and well-tolerated with no serious adverse events recorded. This study is unable to assess the efficacy of the LeVe CPAP System; therefore, formal comparative studies are required to inform further use.
Sections du résumé
BACKGROUND
BACKGROUND
Continuous positive airway pressure (CPAP) has been a key treatment modality for Coronavirus Disease 2019 (COVID-19) worldwide. Globally, the demand for CPAP outstripped the supply during the pandemic. The LeVe CPAP System was developed to provide respiratory support for treatment of COVID-19 and tailored for use in low- and middle-income country (LMIC) settings. Prior to formal trial approval, received in November 2021, these devices were used in extremis to support critically unwell adult patients requiring non-invasive ventilatory support.
METHODS
METHODS
This is a retrospective descriptive review of adult patients with COVID-19 pneumonitis, who were treated with advanced respiratory support (CPAP and/or high-flow nasal oxygen, HFNO) at Mengo Hospital, Uganda. Patients were treated with the LeVe CPAP System, Elisa CPAP and/or AIRVO™ HFNO. Treatment was escalated per standard local protocols for respiratory failure, and CPAP was the maximum respiratory support available. Data were collected on patient characteristics, length of time of treatment, clinical outcome, and any adverse events.
RESULTS
RESULTS
Overall 333 patients were identified as COVID-19 positive, 44 received CPAP ± HFNO of which 43 were included in the study. The median age was 58 years (range 28-91 years) and 58% were female. The median duration of advanced respiratory support was 7 days (range 1-18 days). Overall (all device) mortality was 49% and this was similar between those started on the LeVe CPAP System and those started non-LeVe CPAP System devices (50% vs 47%).
CONCLUSIONS
CONCLUSIONS
The LeVe CPAP system was the most used CPAP device during the pandemic, bringing the hospital's number of available HFNO/CPAP devices from two to 14. They were a critical resource for providing respiratory support to the sickest group of patients when no alternative devices were available. The devices appear to be safe and well-tolerated with no serious adverse events recorded. This study is unable to assess the efficacy of the LeVe CPAP System; therefore, formal comparative studies are required to inform further use.
Identifiants
pubmed: 37545001
doi: 10.1186/s41182-023-00533-9
pii: 10.1186/s41182-023-00533-9
pmc: PMC10405477
doi:
Types de publication
Journal Article
Langues
eng
Pagination
42Informations de copyright
© 2023. Japanese Society of Tropical Medicine.
Références
BMC Res Notes. 2012 Sep 01;5:475
pubmed: 22937769
Lancet. 2021 Aug 7;398(10299):485-486
pubmed: 34364515
J Pers Med. 2021 Sep 03;11(9):
pubmed: 34575661
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767
Crit Care. 2020 Jan 30;24(1):28
pubmed: 32000806
Diagnostics (Basel). 2021 Dec 02;11(12):
pubmed: 34943496
J Crit Care. 2020 Feb;55:95-99
pubmed: 31715537
Acute Crit Care. 2022 Feb;37(1):71-83
pubmed: 35279978
Int J Infect Dis. 2021 Dec;113 Suppl 1:S16-S21
pubmed: 33757874
BMJ Glob Health. 2021 Dec;6(12):
pubmed: 34853031
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
J Intensive Care Soc. 2022 Nov;23(4):398-406
pubmed: 36751359
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32398301
N Engl J Med. 2020 Jul 16;383(3):e11
pubmed: 32302075
Lancet. 2021 May 22;397(10288):1885-1894
pubmed: 34022988
Front Med Technol. 2021 Aug 24;3:715969
pubmed: 35047948
J Crit Care. 2021 Feb;61:76-81
pubmed: 33099204
ERJ Open Res. 2021 Oct 04;7(4):
pubmed: 34611525
Respir Med. 2006 Dec;100(12):2235-8
pubmed: 16678394
Lancet. 2020 Mar 14;395(10227):841-842
pubmed: 32113508
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221113663
pubmed: 35861299
Lancet. 2020 Mar 14;395(10227):871-877
pubmed: 32087820
Lancet. 2021 Mar 6;397(10277):868-869
pubmed: 33676621
BMJ Open Respir Res. 2020 Jul;7(1):
pubmed: 32624495